Trial · NCT02409342
Adverse events352
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 352
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 120 | 263 | 153 |
| other | Anaemia | Blood and lymphatic system disorders | Atezolizumab | 50 | 286 | 73 |
| other | Leukopenia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 21 | 263 | 31 |
| other | Leukopenia | Blood and lymphatic system disorders | Atezolizumab | 4 | 286 | 6 |
| other | Neutropenia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 71 | 263 | 128 |
| other | Neutropenia | Blood and lymphatic system disorders | Atezolizumab | 5 | 286 | 7 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 40 | 263 | 62 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Atezolizumab | 8 | 286 | 8 |
| other | Hypothyroidism | Endocrine disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 3 | 263 | 3 |
| other | Hypothyroidism | Endocrine disorders | Atezolizumab | 27 | 286 | 28 |
| other | Constipation | Gastrointestinal disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 58 | 263 | 75 |
| other | Constipation | Gastrointestinal disorders | Atezolizumab | 42 | 286 | 48 |
| other | Diarrhoea | Gastrointestinal disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 30 | 263 | 39 |
| other | Diarrhoea | Gastrointestinal disorders | Atezolizumab | 39 | 286 | 55 |
| other | Nausea | Gastrointestinal disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 88 | 263 | 148 |
| other | Nausea | Gastrointestinal disorders | Atezolizumab | 42 | 286 | 49 |
| other | Stomatitis | Gastrointestinal disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 14 | 263 | 16 |
| other | Stomatitis | Gastrointestinal disorders | Atezolizumab | 12 | 286 | 14 |
| other | Vomiting | Gastrointestinal disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 34 | 263 | 45 |
| other | Vomiting | Gastrointestinal disorders | Atezolizumab | 21 | 286 | 27 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02409342/events